Treatment of Hemophilia B with a New Clotting-Factor Concentrate

Abstract

A new concentrate of clotting factors II, VII, IX and X, made from pooled human plasma collected in citrate anticoagulant by a process involving the adsorption of the effluent from Cohn fraction I on DEAE Sephadex and fractional elution of adsorbed material, proved effective for prophylaxis and treatment of acute bleeding episodes. The net return in vivo 15 minutes after injection was approximately 40 per cent of the activity measured in vitro. In 20 kinetic studies various values were: factor IX activity at zero time, 58.7 per cent; half-life of the first component of the disappearance curve, four and six-tenths hours; half-life of the second component, 31.5 hours; equilibration time between first and second components, 22.1 hours; and apparent volume of distribution, 2.7 times plasma volume. The distribution and turnover rates were similar to those found previously with plasma in three of the same patients and to results reported by others with British and French concentrates.